Skip to main content
Premium Trial:

Request an Annual Quote

BioMrieux and ExonHit Extend Alliance to Develop Microarrays for Early Cancer Detection

NEW YORK, Oct. 13 (GenomeWeb News) - BioMérieux and ExonHit have extended their collaboration for six years to develop microarray-based diagnostics for early cancer detection, the firms said today.
The alliance began in 2003 with the aim of developing diagnostics for breast cancer. It has now been enlarged to other types of cancers, including colon, prostate, and lung.

The objective of the collaboration is to develop microarrays that can detect genomic cancer markers in blood or tumor samples. The chips would be based on ExonHit's gene-expression patents and bioMérieux's diagnostics experience.

Terms of the agreement call for ExonHit to grants bioMérieux an exclusive license to use its technology and methods in the field of blood diagnostics, gene profiling, and microarray design.

In exchange, bioMérieux will fund ExonHit's R&D costs for each cancer studied. There will be a minimum of five research programs. ExonHit will also receive milestone payments for each key milestone that is reached as well as royalties on future product sales, the partners said today.


Financial details were not disclosed.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.